Clinical Trials in Lutsk, Ukraine
8 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca1,160 enrolled363 locationsNCT07082738
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled124 locationsNCT06997497
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled212 locationsNCT06345729
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 2
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
Mirador Therapeutics, Inc.140 enrolled66 locationsNCT07113522
Recruiting
Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
ColitisInflammatory Bowel DiseasesUlcerative Colitis+1 more
Spyre Therapeutics, Inc.645 enrolled126 locationsNCT07012395
Recruiting
Phase 1Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Xencor, Inc.270 enrolled40 locationsNCT06619990
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled140 locationsNCT07011745
Recruiting
Phase 3
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
HER2 MutationAdvanced Non-Small Cell Lung Cancer
Bayer278 enrolled283 locationsNCT06452277
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 3
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Multiple Sclerosis
Hoffmann-La Roche500 enrolled44 locationsNCT06675955
Recruiting
Phase 3
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Advanced (Unresectable or Metastatic) Melanoma
mAbxience Research S.L.632 enrolled19 locationsNCT07221734
Recruiting
iCaReMe Global Registry
Heart FailureHypertensionChronic Kidney Disease+1 more
AstraZeneca35,000 enrolled55 locationsNCT03549754